
    
      This study is comprised of both a rIX-FP dose-escalation safety segment (25, 50 and 75 IU/kg
      of rIX-FP), and PK evaluation of rIX-FP after a single dose of 50 IU/kg, as well as PK
      evaluation after a single dose of 50 IU/kg of the previously given Factor IX (FIX) product
      (recombinant FIX [rFIX] or plasma derived FIX [pdFIX]) which is used as the reference
      product.
    
  